✦ LIBER ✦

Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase

✍ Scribed by Toru Kiguchi; Tetsuzo Tauchi; Yoshikazu Ito; Keisuke Miyazawa; Yukihiko Kimura; Kazuma Ohyashiki

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 485 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.04.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of imatinib dose escalation in

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 3 views

Imatinib mesylate induces hypophosphatem

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

Erythropoietin is effective in improving

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

✍ Jorge Cortes; Susan O'Brien; Alfonso Quintas; Francis Giles; Jianquin Shan; Mary 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and ≥ Grade 3 myelosuppression is reported in approximately 10% of patients. ## METHODS The authors investigated the prognostic significance of anemia occu

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Persistent neutropenia in chronic myelog

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

The significance of myelosuppression dur

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera